{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T01:20:22Z","timestamp":1787707222364,"version":"build-2784847793"},"reference-count":70,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Diseases Now"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.idnow.2026.105319","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T16:34:44Z","timestamp":1782405284000},"page":"105319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S","title":["Antibiotic treatment of male urinary tract infections: scientific rationale behind the 2026 SPILF guidelines"],"prefix":"10.1016","volume":"56","author":[{"given":"Emmanuel","family":"Forestier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Soudais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvan","family":"Caspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Etienne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Milacic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Orcel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Roubaud-Baudron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Vall\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Lafaurie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idnow.2026.105319_bb0005","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.medmal.2018.03.005","article-title":"Practice guidelines for the management of adult community-acquired urinary tract infections","volume":"48","author":"Caron","year":"2018","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.idnow.2026.105319_bb0010","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2334-8-12","article-title":"Acute bacterial prostatitis: heterogeneity in diagnostic criteria and management. Retrospective multicentric analysis of 371 patients diagnosed with acute prostatitis","volume":"8","author":"Etienne","year":"2008","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.idnow.2026.105319_bb0015","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/fampra\/cmac068","article-title":"Guidelines for the management of male urinary tract infections in primary care: a lack of international consensus\u2014a systematic review of the literature","volume":"40","author":"Soudais","year":"2023","journal-title":"Fam Pract"},{"key":"10.1016\/j.idnow.2026.105319_bb0020","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.idnow.2020.12.001","article-title":"Anti-infectious treatment duration: the SPILF and GPIP French guidelines and recommendations","volume":"51","author":"Gauzit","year":"2021","journal-title":"Infect Dis Now"},{"key":"10.1016\/j.idnow.2026.105319_bb0025","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jama.2021.9899","article-title":"Effect of 7 vs 14 days of antibiotic therapy on resolution of symptoms among afebrile men with urinary tract infection: a randomized clinical trial","volume":"326","author":"Drekonja","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.idnow.2026.105319_bb0030","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/23744235.2020.1736329","article-title":"Antibiotic switch after treatment with UTI antibiotics in male patients","volume":"52","author":"Skow","year":"2020","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.idnow.2026.105319_bb0035","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.3399\/BJGP.2022.0354","article-title":"Nitrofurantoin failure in males with an uncomplicated urinary tract infection: a primary care observational cohort study","volume":"73","author":"Platteel","year":"2023","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.idnow.2026.105319_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211098","article-title":"Retrospective evaluation of nitrofurantoin and pivmecillinam for the treatment of lower urinary tract infections in men","volume":"14","author":"Montelin","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.idnow.2026.105319_bb0045","article-title":"No clinical benefit to treating male urinary tract infection longer than seven days: an outpatient database study. Open forum","volume":"6","author":"Germanos","year":"2019","journal-title":"Infect Dis Ther"},{"issue":"2","key":"10.1016\/j.idnow.2026.105319_bb0050","doi-asserted-by":"crossref","DOI":"10.3399\/BJGPO.2023.0207","article-title":"Acute cystitis in men\u2013 a nationwide study from primary care: antibiotic prescriptions, risk factors, and complications","volume":"8","author":"S\u00e6tre","year":"2024","journal-title":"BJGP Open"},{"key":"10.1016\/j.idnow.2026.105319_bb0055","article-title":"Nitrofurantoin failure in elderly men: a retrospective observational study","volume":"9","author":"Wolterink","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.idnow.2026.105319_bb0060","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/02813432.2020.1794409","article-title":"Different antibiotic regimes in men diagnosed with lower urinary tract infection \u2013 a retrospective register-based study","volume":"38","author":"Kornf\u00e4lt Isberg","year":"2020","journal-title":"Scand J Prim Health Care"},{"key":"10.1016\/j.idnow.2026.105319_bb0065","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/02813432.2020.1718301","article-title":"Retrospective study of men with E. Coli UTI treated with an oral antibiotic, and risk for a new prescription or hospital admission due to UTI","volume":"38","author":"Jans\u00e5ker","year":"2020","journal-title":"Scand J Prim Health Care"},{"key":"10.1016\/j.idnow.2026.105319_bb0070","article-title":"Trimethoprim use for urinary tract infection and risk of adverse outcomes in older patients: cohort study","volume":"361","author":"Crellin","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.idnow.2026.105319_bb0075","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.2147\/IDR.S209255","article-title":"Pivmecillinam compared to other antimicrobials for community-acquired urinary tract infections with Escherichia coli, ESBL-producing or not \u2013 a retrospective cohort study","volume":"12","author":"Jans\u00e5ker","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.idnow.2026.105319_bb0080","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1177\/1756287215581556","article-title":"Effectiveness and safety of nitrofurantoin in outpatient male veterans","volume":"7","author":"Ingalsbe","year":"2015","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.idnow.2026.105319_bb0085","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/2013.jamainternmed.829","article-title":"Urinary tract infection in male veterans: treatment patterns and outcomes","volume":"173","author":"Drekonja","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.idnow.2026.105319_bb0090","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/23744235.2025.2566723","article-title":"Narrow-spectrum antibiotics to male patients with acute cystitis - a retrospective longitudinal study","volume":"58","author":"Snaebj\u00f6rnsson Arnljots","year":"2026","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.idnow.2026.105319_bb0095","article-title":"Choice of empirical antibiotic therapy and adverse outcomes in older adults with suspected urinary tract infection: cohort study. Open forum","volume":"6","author":"Ahmed","year":"2019","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.idnow.2026.105319_bb0100","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1093\/jac\/dkz211","article-title":"Treatment duration of pivmecillinam in men, non-pregnant and pregnant women for community-acquired urinary tract infections caused by Escherichia coli: a retrospective Danish cohort study","volume":"74","author":"Boel","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idnow.2026.105319_bb0105","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1093\/jac\/dkw178","article-title":"Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis","volume":"71","author":"Seroy","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idnow.2026.105319_bb0110","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1186\/s12879-016-1888-1","article-title":"Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study","volume":"16","author":"Matthews","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.idnow.2026.105319_bb0115","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijantimicag.2006.08.039","article-title":"Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections","volume":"29","author":"Pullukcu","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idnow.2026.105319_bb0120","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004157","article-title":"Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study","volume":"3","author":"Qiao","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.idnow.2026.105319_bb0125","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000085625","article-title":"Fosfomycin tromethamine in uncomplicated urinary tract infections: a clinical study","volume":"51","author":"Bonfiglio","year":"2005","journal-title":"Chemotherapy"},{"key":"10.1016\/j.idnow.2026.105319_bb0130","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1179\/joc.2010.22.5.355","article-title":"Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection","volume":"22","author":"Senol","year":"2010","journal-title":"J Chemother"},{"key":"10.1016\/j.idnow.2026.105319_bb0135","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000304","article-title":"Comparative effectiveness of different oral antibiotics regimens for treatment of urinary tract infection in outpatients: an analysis of national representative claims database","volume":"93","author":"Lee","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.idnow.2026.105319_bb0140","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3122\/jabfm.2016.06.160065","article-title":"5-day versus 10-day course of fluoroquinolones in outpatient males with a urinary tract infection (UTI)","volume":"29","author":"Mospan","year":"2016","journal-title":"J Am Board Fam Med"},{"key":"10.1016\/j.idnow.2026.105319_bb0145","article-title":"The latest updates on the proper use of fluoroquinolones - actualisation 2025 update by the SPILF and the GPIP","volume":"55","author":"Vuotto","year":"2025","journal-title":"Infect Dis Now"},{"key":"10.1016\/j.idnow.2026.105319_bb0150","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(25)02171-3","article-title":"Clinical and bacteriological effectiveness of three different short-course antibiotic regimens and single-dose fosfomycin for uncomplicated lower urinary tract infections in women (SCOUT): a pragmatic, multicentre, open-label, randomised clinical trial","volume":"407","author":"Llor","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.idnow.2026.105319_bb0155","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S1473-3099(21)00407-2","article-title":"The clinical and microbiological efficacy of temocillin versus cefotaxime in adults with febrile urinary tract infection, and its effects on the intestinal microbiota: a randomised multicentre clinical trial in Sweden","volume":"22","author":"Edlund","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.idnow.2026.105319_bb0160","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/cid\/ciad009","article-title":"Defining the optimal duration of therapy for hospitalized patients with complicated urinary tract infections and associated Bacteremia","volume":"76","author":"McAteer","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idnow.2026.105319_bb0165","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.20166","article-title":"Oral \u03b2-lactam antibiotics vs fluoroquinolones or trimethoprim-sulfamethoxazole for definitive treatment of Enterobacterales Bacteremia from a urine source","volume":"3","author":"Sutton","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.idnow.2026.105319_bb0170","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1093\/cid\/ciz181","article-title":"Fosfomycin for injection (ZTI-01) versus piperacillin-tazobactam for the treatment of complicated urinary tract infection including acute pyelonephritis: ZEUS, a phase 2\/3 randomized trial","volume":"69","author":"Kaye","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idnow.2026.105319_bb0175","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.37277","article-title":"Effectiveness of Fosfomycin for the treatment of multidrug-resistant Escherichia coli Bacteremic urinary tract infections: a randomized clinical trial","volume":"5","author":"Sojo-Dorado","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.idnow.2026.105319_bb0180","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.cmi.2025.01.007","article-title":"Effectiveness and tolerability of intravenous fosfomycin in treating complicated urinary tract infections caused by Escherichia coli: a prospective cohort study from the FOSFOMIC project","volume":"31","author":"Moreno-Mellado","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idnow.2026.105319_bb0185","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1093\/jac\/dkaa369","article-title":"Effectiveness and safety of an institutional aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis","volume":"75","author":"Elbaz","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idnow.2026.105319_bb0190","first-page":"458","article-title":"Aminoglycoside versus carbapenem or piperacillin\/tazobactam treatment for bloodstream infections of urinary source caused by gram-negative ESBL-producing Enterobacteriaceae","volume":"75","author":"Zohar","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idnow.2026.105319_bb0195","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJMoa1801467","article-title":"Once-daily Plazomicin for complicated urinary tract infections","volume":"380","author":"Wagenlehner","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.idnow.2026.105319_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2025.107696","article-title":"Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: a systematic review and meta-analysis","volume":"67","author":"Kunwar","year":"2026","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idnow.2026.105319_bb0205","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.0954-6820.1980.tb09725.x","article-title":"Failure of excessive doses of ampicillin to prevent bacterial relapse in the treatment of acute pyelonephritis","volume":"207","author":"Ode","year":"1980","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.idnow.2026.105319_bb0210","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.0954-6820.1988.tb15899.x","article-title":"One or three weeks\u2019 treatment of acute pyelonephritis? A double-blind comparison, using a fixed combination of pivampicillin plus pivmecillinam","volume":"223","author":"Jernelius","year":"1988","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.idnow.2026.105319_bb0215","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3390\/idr14040067","article-title":"Oral Fosfomycin formulation in bacterial prostatitis: new role for an old molecule-brief literature review and clinical considerations","volume":"14","author":"Marino","year":"2022","journal-title":"Infect Dis Rep"},{"key":"10.1016\/j.idnow.2026.105319_bb0220","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3390\/antibiotics11020198","article-title":"Efficacy and safety of Oral Fosfomycin-trometamol in male urinary tract infections with multidrug-resistant Enterobacterales","volume":"11","author":"Bouiller","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.idnow.2026.105319_bb0225","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02136-23","article-title":"Oral fosfomycin for treatment of acute bacterial prostatitis caused by multidrug-resistant Enterobacterales","volume":"11","author":"Burgos","year":"2023","journal-title":"Microbiol Spectrum"},{"issue":"5","key":"10.1016\/j.idnow.2026.105319_bb0230","first-page":"1234","article-title":"Fosfomycin vs ertapenem for outpatient treatment of complicated urinary tract infections: a multicenter retrospective cohort study","volume":"78","author":"Wald-Dickler","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idnow.2026.105319_bb0235","first-page":"155","article-title":"Chronic bacterial prostatitis and relapsing Enterococcus faecalis bacteraemia successfully treated with moxifloxacin","volume":"56","author":"van Nieuwkoop","year":"2008","journal-title":"J Inf Secur"},{"key":"10.1016\/j.idnow.2026.105319_bb0240","doi-asserted-by":"crossref","first-page":"7156","DOI":"10.1128\/AAC.01988-15","article-title":"Enterococcus faecalis-related prostatitis successfully treated with moxifloxacin","volume":"59","author":"Pilmis","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idnow.2026.105319_bb0245","first-page":"175","article-title":"Linezolid for the treatment of urinary tract infections caused by vancomycin-resistant enterococci","volume":"9","author":"Wingler","year":"2021","journal-title":"Pharmacy (Basel)"},{"key":"10.1016\/j.idnow.2026.105319_bb0250","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1007\/s10096-024-04923-7","article-title":"Linezolid in enterococcal urinary tract infection: a multicentre study","volume":"43","author":"Malinowski","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.idnow.2026.105319_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106361","article-title":"Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case-control study","volume":"58","author":"Delory","year":"2021","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.idnow.2026.105319_bb0260","article-title":"Real-life temocillin use in Greater Paris area, effectiveness and risk factors for failure in infections caused by ESBL-producing Enterobacterales: a multicentre retrospective study","volume":"5","author":"Dinh","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.idnow.2026.105319_bb0265","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10096-019-03701-0","article-title":"Efficacy of cefoxitin versus carbapenem in febrile male urinary tract infections caused by extended spectrum beta-lactamase\u2013producing Escherichia coli: a multicenter retrospective cohort study with propensity score analysis","volume":"39","author":"Senard","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.idnow.2026.105319_bb0270","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.idnow.2026.105319_bb0275","article-title":"Assessing clinical cure of empirical piperacillin\/tazobactam for ESBL urinary tract infections (ACCEPT-UTI)","volume":"5","author":"Stefanos","year":"2023","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.idnow.2026.105319_bb0280","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/0036554021000026988","article-title":"Ciprofloxacin for 2 or 4 weeks in the treatment of febrile urinary tract infection in men: a randomized trial with a 1 year follow-up","volume":"35","author":"Ulleryd","year":"2003","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.idnow.2026.105319_bb0285","first-page":"2154","article-title":"Antimicrobial for 7 or 14 days for febrile urinary tract infection in men: a Multicenter noninferiority double-blind, placebo-controlled","volume":"76","author":"Lafaurie","year":"2023","journal-title":"Randomized Clinical Trial Clin Infect Dis"},{"key":"10.1016\/j.idnow.2026.105319_bb0290","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0924-8579(95)00011-V","article-title":"A sequential study of intravenous and oral fleroxacin for 7 or 14 days in the treatment of complicated urinary tract infections","volume":"6","author":"de Gier","year":"1995","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idnow.2026.105319_bb0295","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1185\/030079907X233340","article-title":"A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and\/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis","volume":"23","author":"Klausner","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.idnow.2026.105319_bb0300","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urology.2007.09.002","article-title":"A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400\/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis","volume":"71","author":"Peterson","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.idnow.2026.105319_bb0305","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12916-017-0835-3","article-title":"Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women","volume":"15","author":"Van Nieuwkoop","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.idnow.2026.105319_bb0310","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11255-017-1507-0","volume":"49","author":"Ren","year":"2017","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.idnow.2026.105319_bb0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197302","article-title":"Stopping the effective non-fluoroquinolone antibiotics at day 7 vs continuing until day 14 in adults with acute pyelonephritis requiring hospitalization: a randomized non-inferiority trial","volume":"13","author":"Rudrabhatla","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.idnow.2026.105319_bb0320","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/cid\/ciy1054","article-title":"Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative Bacteremia: a noninferiority randomized controlled trial","volume":"69","author":"Yahav","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idnow.2026.105319_bb0325","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1001\/jama.2020.6348","article-title":"Effect of C-reactive protein-guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated gram-negative Bacteremia: a randomized clinical trial","volume":"323","author":"von Dach","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.idnow.2026.105319_bb0330","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cmi.2021.09.001","article-title":"Seven-versus 14-day course of antibiotics for the treatment of bloodstream infections by Enterobacterales: a randomized, controlled trial","volume":"28","author":"Molina","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idnow.2026.105319_bb0335","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMoa2404991","article-title":"Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections","volume":"392","author":"BALANCE Investigators, for the Canadian Critical Care Trials Group, the Association of Medical Microbiology and Infectious Disease Canada Clinical Research Network, the Australian and New Zealand Intensive Care Society Clinical Trials Group, and the Australasian Society for Infectious Diseases Clinical Research Network","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.idnow.2026.105319_bb0340","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1046\/j.1464-410x.1999.00252.x","article-title":"A double-blind, randomized, controlled multicentre study to compare the efficacy of ciprofloxacin with pivampicillin as oral therapy for epididymitis in men over 40 years of age","volume":"84","author":"Eickhoff","year":"1999","journal-title":"BJU Int"},{"key":"10.1016\/j.idnow.2026.105319_bb0345","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/bjs.1800710921","article-title":"The aetiology and management of acute epididymitis","volume":"71","author":"Redfern","year":"1984","journal-title":"Br J Surg"},{"key":"10.1016\/j.idnow.2026.105319_bb0350","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1177\/0956462417699356","article-title":"The 2016 European guideline on the management of epididymo-orchitis","volume":"28","author":"Street","year":"2017","journal-title":"Int J STD AIDS"}],"container-title":["Infectious Diseases Now"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266699192600076X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266699192600076X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:45:20Z","timestamp":1787705120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266699192600076X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S266699192600076X"],"URL":"https:\/\/doi.org\/10.1016\/j.idnow.2026.105319","relation":{},"ISSN":["2666-9919"],"issn-type":[{"value":"2666-9919","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibiotic treatment of male urinary tract infections: scientific rationale behind the 2026 SPILF guidelines","name":"articletitle","label":"Article Title"},{"value":"Infectious Diseases Now","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idnow.2026.105319","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"105319"}}